These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35151332)

  • 1. The impact of the private sector co-payment mechanism (PSCM) on the private market for ACT in Nigeria: results of the 2018 cross-sectional outlet and household market surveys.
    Edwards HM; Sarwar R; Mahmud P; Emmanuel S; Maxwell K; Tibenderana JK
    Malar J; 2022 Feb; 21(1):42. PubMed ID: 35151332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The private sector market for malaria rapid diagnostic tests in Nigeria: results of the 2018 market survey.
    Edwards HM; Sarwar R; Mahmud P; Emmanuel S; Maxwell K; Tibenderana JK
    Malar J; 2022 Jun; 21(1):190. PubMed ID: 35710474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism.
    ; Tougher S; Hanson K; Goodman C
    Malar J; 2017 Apr; 16(1):173. PubMed ID: 28441956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.
    O'Connell KA; Gatakaa H; Poyer S; Njogu J; Evance I; Munroe E; Solomon T; Goodman C; Hanson K; Zinsou C; Akulayi L; Raharinjatovo J; Arogundade E; Buyungo P; Mpasela F; Adjibabi CB; Agbango JA; Ramarosandratana BF; Coker B; Rubahika D; Hamainza B; Chapman S; Shewchuk T; Chavasse D
    Malar J; 2011 Oct; 10():326. PubMed ID: 22039838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The malaria testing and treatment landscape in Benin.
    ; Zinsou C; Cherifath AB
    Malar J; 2017 Apr; 16(1):174. PubMed ID: 28446236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has Tanzania embraced the green leaf? Results from outlet and household surveys before and after implementation of the Affordable Medicines Facility-malaria.
    Thomson R; Festo C; Johanes B; Kalolella A; Bruxvoort K; Nchimbi H; Tougher S; Cairns M; Taylor M; Kleinschmidt I; Ye Y; Mann A; Ren R; Willey B; Arnold F; Hanson K; Kachur SP; Goodman C
    PLoS One; 2014; 9(5):e95607. PubMed ID: 24816649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing availability, prices, and market share of quality-assured malaria ACT and RDT in the private retail sector in Nigeria and Uganda.
    Woldeghebriel M; Aso E; Berlin E; Fashanu C; Kirumira SN; Lam F; Mugerwa R; Nakiganda J; Olaleye T; Opigo J; Osinupebi F; Priestley N; Stringham R; Uhomoibhi P; Visser T; Ward A; Wiwa O; Woolsey A
    Malar J; 2024 Feb; 23(1):41. PubMed ID: 38321459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The malaria testing and treatment landscape in mainland Tanzania, 2016.
    ; Michael D; Mkunde SP
    Malar J; 2017 Apr; 16(1):202. PubMed ID: 28521811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data.
    Tougher S; ; Ye Y; Amuasi JH; Kourgueni IA; Thomson R; Goodman C; Mann AG; Ren R; Willey BA; Adegoke CA; Amin A; Ansong D; Bruxvoort K; Diallo DA; Diap G; Festo C; Johanes B; Juma E; Kalolella A; Malam O; Mberu B; Ndiaye S; Nguah SB; Seydou M; Taylor M; Rueda ST; Wamukoya M; Arnold F; Hanson K
    Lancet; 2012 Dec; 380(9857):1916-26. PubMed ID: 23122217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When it just won't go away: oral artemisinin monotherapy in Nigeria, threatening lives, threatening progress.
    ; Ujuju C; Anyanti J; Newton PN; Ntadom G
    Malar J; 2017 Dec; 16(1):489. PubMed ID: 29246208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral artemisinin monotherapy removal from the private sector in Eastern Myanmar between 2012 and 2014.
    Khin HS; Aung T; Thi A; White C;
    Malar J; 2016 May; 15(1):286. PubMed ID: 27216408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of successful malaria case management policy implementation in Cambodia: results from national ACTwatch outlet surveys.
    ; Novotny J; Singh A; Dysoley L; Sovannaroth S; Rekol H
    Malar J; 2016 Apr; 15():194. PubMed ID: 27059952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The malaria testing and treatment market in Kinshasa, Democratic Republic of the Congo, 2013.
    ; Mpanya G; Tshefu A; Likwela JL
    Malar J; 2017 Feb; 16(1):94. PubMed ID: 28241832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Misuse of Artemisinin Combination Therapies by Clients of Medicine Retailers Suspected to Have Malaria Without Prior Parasitological Confirmation in Nigeria.
    Nwokolo E; Ujuju C; Anyanti J; Isiguzo C; Udoye I; BongosIkwue E; Ezire O; Raji M; Oyibo WA
    Int J Health Policy Manag; 2018 Jun; 7(6):542-548. PubMed ID: 29935131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study.
    Talisuna AO; Daumerie PG; Balyeku A; Egan T; Piot B; Coghlan R; Lugand M; Bwire G; Rwakimari JB; Ndyomugyenyi R; Kato F; Byangire M; Kagwa P; Sebisubi F; Nahamya D; Bonabana A; Mpanga-Mukasa S; Buyungo P; Lukwago J; Batte A; Nakanwagi G; Tibenderana J; Nayer K; Reddy K; Dokwal N; Rugumambaju S; Kidde S; Banerji J; Jagoe G
    Malar J; 2012 Oct; 11():356. PubMed ID: 23107021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The malaria testing and treatment landscape in Kenya: results from a nationally representative survey among the public and private sector in 2016.
    ; Musuva A; Ejersa W; Kiptui R; Memusi D; Abwao E
    Malar J; 2017 Dec; 16(1):494. PubMed ID: 29268789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Private sector role, readiness and performance for malaria case management in Uganda, 2015.
    ; Kaula H; Buyungo P; Opigo J
    Malar J; 2017 May; 16(1):219. PubMed ID: 28545583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets.
    Ocan M; Nambatya W; Otike C; Nakalembe L; Nsobya S
    PLoS One; 2024; 19(3):e0295198. PubMed ID: 38536824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-malarial landscape in Myanmar: results from a nationally representative survey among community health workers and the private sector outlets in 2015/2016.
    ; Thein ST; Khin HSS; Thi A
    Malar J; 2017 Apr; 16(1):129. PubMed ID: 28438197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the availability and affordability of subsidised artemisinin combination therapy in the private drug retail sector in rural Ghana: before and after the introduction of the AMFm subsidy.
    Ansah EK; Whitty CJ; Bart-Plange C; Gyapong M
    Int Health; 2016 Nov; 8(6):427-432. PubMed ID: 27744327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.